Post Covid 19 clinical trials

Explore recruiting post covid 19 clinical trials.

Recruiting post covid 19 studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Post Covid 19 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post COVID-19 Condition

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II proof-of-concept, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of plitidepsin in adults with post-COVID-19 Condition (PCC)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND CLINICAL TRIAL TO INVESTIGATE TREATMENT EFFECTS AND SAFETY OF GINKGO BILOBA EXTRACT EGB 761® IN PARTICIPANTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYNDROME

Spain, Germany, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in post-COVID-19 syndrome (PCS) - PoCoVIT

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Platform randomised trial of treatments for COVID-19 in general practice

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Double-blind, Randomized, Placebo-controlled Phase 3 study Evaluating Efficacy and Safety of IgPro20 (subcutaneous immunoglobulin, HIZENTRA®) in post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)

Germany, Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Post Covid 19 trials by city

Post Covid 19 in Toronto Post Covid 19 in Vancouver Post Covid 19 in Montreal Post Covid 19 in Calgary Post Covid 19 in Edmonton Post Covid 19 in Ottawa Post Covid 19 in Winnipeg Post Covid 19 in Quebec City Post Covid 19 in Hamilton Post Covid 19 in Kitchener Post Covid 19 in London Post Covid 19 in Halifax Post Covid 19 in New York Post Covid 19 in Los Angeles Post Covid 19 in Chicago Post Covid 19 in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease